ECBF supports Series-C of Aphea.Bio in the amount of 70 million euros

ECBF is again supporting Aphea.Bio, a company that develops agro-biological products to improve fertilization and fungus control in agriculture. The investment contributes to the implementation of the EU Green Deal objectives by reducing fertilizer use and decreasing dependence on chemical pesticides.

Luxembourg - Aphea.Bio, a Belgian agricultural technology company, has successfully closed a €70 million Series C financing. The financing round was led by Innovation Industries, joined by Korys Investments, the Bill & Melinda Gates Foundation, SFPIM and BNP Paribas Fortis, ECBF and existing shareholders. The main objective of this investment is to promote sustainable agricultural practices.

Thanks to this financing, Aphea.Bio will be able to drive its growth and consolidate its position in the development of organic products. The company will use the funds to advance research and development of organic solutions, scale product launches, expand market reach, and expand distribution of its products.

We are pleased to have secured Series C funding, which furthers our mission to enable sustainable, profitable and reliable agriculture

Isabel Vercauteren, CEO Aphea.Bio

Aphea.Bio CEO Isabel Vercauteren emphasizes the importance of this funding to the company. She is excited about the opportunity to expand the company's activities and bring its products to market on a larger scale to address pressing agricultural challenges and meet the needs of farmers worldwide.

ECBF, which was already involved in Aphea.Bio's Series B financing, supports the transition to a sustainable bioeconomy and biobased circular economy. The Fund recognized Aphea.Bio's potential early on and participated again in the Series C financing.

Thanks to the oversubscribed Series C, Aphea.Bio will be able to revolutionize agriculture through science-based microbial solutions.

Stéphane Roussel, Partner ECBF

Stéphane Roussel, Partner at ECBF, comments that thanks to this funding, Aphea.Bio will be able to revolutionize agriculture with science-based microbial solutions. He expresses pride in being able to support Aphea.Bio's experienced team on its path to becoming a global company and emphasizes the joint efforts of both parties for a more sustainable agri-food sector.

The €70 million funding comes at a time of growth for Aphea.Bio. The company has built a team of more than 50 scientists and industry specialists and is expanding its research facilities. The company also plans to open a new pilot plant later this year. Aphea.Bio has also made progress in its product portfolio, including the launch of ΛCTIV, a novel biostimulant seed treatment. Other products, such as a biostimulant for corn and a biofungicide, are already in the pipeline.

The ECBF is a fund in the field of bioeconomy and circular economy initiated by the European Union. The fund invests in visionary European entrepreneurs who are driving the transition to a bio-based economy. Established in 2020 with a €100 million commitment from the European Investment Bank (EIB), the ECBF aims to strengthen Europe's leading expertise in circular technologies.